EGRX vs. ZIOP, OMER, PBYI, VACC, CAPR, GALT, OGI, ATOS, IVA, and VERU
Should you be buying Eagle Pharmaceuticals stock or one of its competitors? The main competitors of Eagle Pharmaceuticals include ZIOPHARM Oncology (ZIOP), Omeros (OMER), Puma Biotechnology (PBYI), Vaccitech (VACC), Capricor Therapeutics (CAPR), Galectin Therapeutics (GALT), Organigram (OGI), Atossa Therapeutics (ATOS), Inventiva (IVA), and Veru (VERU). These companies are all part of the "medical" sector.
Eagle Pharmaceuticals (NASDAQ:EGRX) and ZIOPHARM Oncology (NASDAQ:ZIOP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, community ranking, profitability, institutional ownership, analyst recommendations, earnings and valuation.
In the previous week, Eagle Pharmaceuticals had 3 more articles in the media than ZIOPHARM Oncology. MarketBeat recorded 3 mentions for Eagle Pharmaceuticals and 0 mentions for ZIOPHARM Oncology. Eagle Pharmaceuticals' average media sentiment score of 0.82 beat ZIOPHARM Oncology's score of 0.00 indicating that Eagle Pharmaceuticals is being referred to more favorably in the media.
Eagle Pharmaceuticals' return on equity of 0.00% beat ZIOPHARM Oncology's return on equity.
Eagle Pharmaceuticals presently has a consensus target price of $17.00, indicating a potential upside of 389.91%.
85.4% of Eagle Pharmaceuticals shares are held by institutional investors. Comparatively, 51.0% of ZIOPHARM Oncology shares are held by institutional investors. 28.9% of Eagle Pharmaceuticals shares are held by company insiders. Comparatively, 5.2% of ZIOPHARM Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Eagle Pharmaceuticals has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Comparatively, ZIOPHARM Oncology has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500.
Eagle Pharmaceuticals has higher revenue and earnings than ZIOPHARM Oncology. ZIOPHARM Oncology is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Eagle Pharmaceuticals received 22 more outperform votes than ZIOPHARM Oncology when rated by MarketBeat users. Likewise, 70.43% of users gave Eagle Pharmaceuticals an outperform vote while only 54.62% of users gave ZIOPHARM Oncology an outperform vote.
Summary
Eagle Pharmaceuticals beats ZIOPHARM Oncology on 12 of the 13 factors compared between the two stocks.
Get Eagle Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eagle Pharmaceuticals Competitors List
Related Companies and Tools
